Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05305547 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
A Phase 3 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,093
- Enrollment target
NCT05305547 is a Phase 3 study that has completed, run by Shionogi. The registered enrollment target is 2,093 participants.
The verdict
NCT05305547, a Phase 3 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,093 participants
- Enrollment target
Study Summary
The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.
Interventions
- DRUG Placebo
- DRUG S-217622
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,093 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2024-05-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05305547
The ClinicalTrials.gov registry entry for NCT05305547 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,093 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05305547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05305547 about?
NCT05305547 is a clinical study titled "A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19". The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.
What is the current status of trial NCT05305547?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,093 participants. The study started on 2022-08-03. Estimated completion is 2024-05-24.
What interventions are being tested in trial NCT05305547?
The interventions under investigation include: Placebo (DRUG), S-217622 (DRUG).
Who is sponsoring clinical trial NCT05305547?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.